“The regulatory perspective: benefits and limits of 3D printed drugs” – Presented by Dr. William Shang, Johnson & Johnson

“The regulatory perspective: benefits and limits of 3D printed drugs” – Presented by Dr. William Shang, Johnson & Johnson. 3DP technology is already up and running in many areas. The future definitely looks promising when considering the idea of 3DPs, but are the regulatory agencies ready for such technology? The presentation will reflect the regulators views and concerns about pharmaceutical development, manufacturing and control of this new technology. Potential clinical and preclinical obstacles in terms of practical use will be addressed as well.

About Dr. William Shang

William Shang is PhD qualified with more than 15 years of industry experience gained pharmaceutical industry. He brings significant regulatory experience in the development and maintenance of medicinal products in terms of preclinical, clinical and CMC dossier requirements.

About Johnson & Johnson

Caring for the world, one person at a time… inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Leave a Reply

Your email address will not be published. Required fields are marked *